Werewolf Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update March 12, 2025
AAVantgarde announces 2 presentations at ARVO 2025 annual meeting: LUCE-1 clinical trial data from Usher 1B program & NHP GLP data from Stargardt disease program March 10, 2025
TScan Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update March 5, 2025
BridgeBio Oncology Therapeutics and Helix Acquisition Corp. II Announce Business Combination Agreement to Create Publicly Listed Biotechnology Company Advancing a Pipeline of RAS and PI3Kα-Targeting Medicines March 3, 2025
Pyxis Oncology Granted FDA Fast Track Designation for PYX-201 Monotherapy in Patients with Recurrent or Metastatic Head and Neck Cancer February 26, 2025
Photys Therapeutics Enters into Exclusive License Agreement with Polymed for Phase 1-Ready IRAK4 Degrader, Furthering its Proximity-based Pipeline and Mission February 20, 2025
